Clinical Trials
14 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT00508443 2026-01-15
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT04106492 2025-11-14
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
Phase 1/2 Terminated
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT05187338 2024-06-25
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2 Recruiting
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT02862288 2016-08-11
TherMO
Centre Hospitalier Universitaire de Besancon
Phase 1/2 Completed
NCT00041808 2005-06-24
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
FeRx
Phase 1/2 Completed